Henry Schein, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Henry Schein, Inc. (Nasdaq: HSIC) provides health care products and services to office-based dental, medical, and animal health practitioners worldwide through its global distribution network. Founded in 1932 and headquartered in Melville, New York, the company distributes more than 300,000 branded and private-label products from over 300 distribution centers across 33 countries and territories; its offerings span dental consumables, equipment, and digital technologies including practice management software such as Dentrix Ascend; medical supplies, pharmaceuticals, diagnostics, and equipment for physician practices, ambulatory surgery centers, and alternate care sites; technology and value-added services encompassing electronic health records, financial services, consulting, and education; as well as global specialty products like dental implants, biomaterials, endodontic, orthodontic, and orthopedic items. Henry Schein serves over 1 million customers, including general dentists, specialists, dental laboratories, veterinary practices, and institutional health care providers, with 2024 sales reaching $12.7 billion. In recent developments, the company expanded its strategic partnership with KKR & Co. in November 2025, amending the agreement to allow KKR to increase its ownership stake up to 19.9% through open-market purchases while targeting over $200 million in operating income improvements; it broadened collaboration with vVARDIS in late 2025, securing exclusive U.S. distribution rights for the drill-free Curodont Fluor Plus product effective January 2026 across general dentistry, orthodontics, and pediatric sectors; Henry Schein also completed acquisitions of medical suppliers including Prism Medical Products in 2021, Shield Healthcare and Mini Pharmacy in 2023, and Acentus in late 2024 to bolster its homecare medical supplies market presence; additionally, it reported record third-quarter 2025 results with raised full-year guidance, including 3%-4% sales growth and mid-single-digit adjusted EBITDA expansion, alongside a $229 million share repurchase program.
Company News
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher
Are Investors Undervaluing Henry Schein (HSIC) Right Now?
What Makes Henry Schein (HSIC) a New Buy Stock
HSIC or SAUHY: Which Is the Better Value Stock Right Now?
Here's Why Henry Schein (HSIC) is a Strong Value Stock
Henry Schein: Growth Is Improving, But The Valuation Stays Cheap
Henry Schein, Inc. (HSIC) Presents at 2026 Global Healthcare Conference Transcript
Applied BioCode Announces Distribution Agreement with Henry Schein
Henry Schein to Participate in Upcoming Investor Conference in September
Henry Schein (HSIC) is an Incredible Growth Stock: 3 Reasons Why
Why Is Henry Schein (HSIC) Up 0.9% Since Last Earnings Report?
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
Is Henry Schein (HSIC) Stock Undervalued Right Now?
505,999 Shares in Henry Schein, Inc. $HSIC Purchased by Bank of New York Mellon Corp
HSIC vs. SAUHY: Which Stock Is the Better Value Option?
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
HSIC Raises 2026 Outlook as Sales and Margin Momentum Accelerates
Empowered Funds LLC Has $851,000 Position in Henry Schein, Inc. $HSIC